New Study Explores if a Vaccine Can Prevent Breast Cancer
Harnessing the immune system to target cancer has long resided on doctors’ wish lists, with very little promise of becoming reality. Because cancer cells are normal cells that mutate to grow out of control, directing the body to destroy these cells is a risky endeavor with potentially dangerous outcomes. Advances in immunotherapy, however, have led to powerful drugs that can help immune cells better distinguish between cancer cells and healthy ones, and researchers are now testing the idea of whether the immune system can be trained to recognize and destroy breast cancer cells in the same way that it dispatches virus...
Source: TIME: Health - November 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news

Implementing ADCs in HER2-Positive Breast Cancer Implementing ADCs in HER2-Positive Breast Cancer
Learn more about the antibody-drug conjugates currently approved as well as those under development for the treatment of HER2-positive breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Ultrasound Enhances Drug Delivery to Treat Brain Metastases Ultrasound Enhances Drug Delivery to Treat Brain Metastases
Proof-of-concept study shows MR-guided focused ultrasound enhances drug delivery to better treat brain metastases in HER2+ breast cancer patients.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 14, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Adding Verzenio to endocrine therapy demonstrated a significant and clinically meaningful reduction in the risk of recurrence in patients with HR+ HER2-, node-positive, high risk early breast cancer and a Ki-67 score of ≥20% Verzenio is the first ... Biopharmaceuticals, Oncology, FDA Eli Lilly, Verzenio, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 13, 2021 Category: Pharmaceuticals Source Type: news

Breakthroughs in Metastatic Breast Cancer From ESMO 2021 Breakthroughs in Metastatic Breast Cancer From ESMO 2021
Dr Javier Cortes presents practice-changing data on metastatic breast cancer from ESMO 2021, including trastuzumab deruxtecan in HER2+ disease, pembrolizumab in TNBC, and ribociclib in HR+/HER2- disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20 Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20
The drug showed clinically meaningful efficacy for patients with treatment-naive nonsmall cell lung cancer HER2 exon 20 mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Trastuzumab Deruxtecan Slows Metastatic Breast Cancer
Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 24, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

' Astonishing' PFS Improvement in Metastatic HER+ Breast Cancer'Astonishing' PFS Improvement in Metastatic HER+ Breast Cancer
Experts hail the"astonishing" improvement in progression-free survival reported with trastuzumab deruxtecan in HER2+ metastatic breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Six Months of Trastuzumab Effective in HER2+ Breast Cancer Six Months of Trastuzumab Effective in HER2+ Breast Cancer
A large-scale data analysis has confirmed that 6 months of trastuzumab is just as effective as 12 months in HER2+ early breast cancer, but the question is whether it will be adopted, say experts.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Neoadjuvant pertuzumab a costly addition for treating HER2+ breast cancer in Portugal
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

ASCO Updates Recommendations for Managing Hereditary Breast Cancer
FRIDAY, July 9, 2021 -- One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2021 Category: Pharmaceuticals Source Type: news

Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
(European Society for Medical Oncology) Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news

Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Dr Kathy Miller shares the'biggest news in the breast cancer world'from ASCO, with presented data showing the benefit of olaparib in patients with high-risk,BRCA-mutated HER2-negative disease.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA approves margetuximab for metastatic HER2-positive breast cancer
On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs
For women with HER2-positive early breast cancer, concurrent therapy with ACE inhibitor lisinopril can help to prevent a decline in left-ventricular ejection fraction (LVEF).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2021 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

' Smart Bomb' Salvage in HER+ Metastatic CRC'Smart Bomb' Salvage in HER+ Metastatic CRC
The higher the HER2 expression, the more benefit patients get from the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mCRC in the salvage setting, according to a phase 2 report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Adding Olaparib Slows High - Risk Early Breast Cancer
Higher rates of invasive disease - free survival seen in adjuvant setting for HER2 - negative early - stage disease with germline BRCA1 or BRCA2 mutations (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

IL-6 Levels Predict Distant Breast Cancer Recurrence IL-6 Levels Predict Distant Breast Cancer Recurrence
Interleukin 6 may be a biomarker for distant recurrence of breast cancer among patients treated for stage II-III HER2-negative disease, investigators have found. The evidence was presented at ASCO 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Adding Olaparib Slows High-Risk Early Breast Cancer
FRIDAY, June 4, 2021 -- The addition of therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in an adjuvant setting improves invasive disease-free survival in early-stage human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer
Basel, 4 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the presentation of new and updated data on giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in people with hormone receptor (HR)-positive, HER2-negative breast cancer. Breast cancer is now the most common cancer in the world, with HR-positive being the most common subtype representing 70% of cases.1,2 Data from these studies will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.“We’re encour...
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news

ECOG-ACRIN research highlights at ASCO 2021
(ECOG-ACRIN Cancer Research Group) Platinum chemotherapy fails for triple-negative breast cancer, basal-like subtype. The first racially diverse trial to look at severe joint pain from aromatase inhibitors shows more postmenopausal Black and Asian women with early breast cancer developed this common/significant syndrome. Less intense therapy for HPV-associated throat cancer shows outstanding three-year survival and quality of life. Inflammation biomarker links to distant recurrence of HER2-negative early breast cancer. Joseph A. Sparano receives ASCO's 2021 Gianni Bonadonna Breast Cancer Award and Lecture. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2021 Category: Cancer & Oncology Source Type: news

Evolving Strategies in Sequencing for HER2+ MBC Therapy Evolving Strategies in Sequencing for HER2+ MBC Therapy
Therapies targeting HER2+ MBC are evolving rapidly. Several recent FDA approvals offer experts an array of new options and prompt a reevaluation of treatments and sequencing strategies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
(University of Texas M. D. Anderson Cancer Center) Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tumor marker may help overcome endocrine treatment-resistant breast cancer
(Sanford Burnham Prebys Medical Discovery Institute) A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

A path to aggressive breast cancer
(Baylor College of Medicine) Following the progression of breast cancer in an animal model revealed a path that transforms a slow-growing cancer type known as estrogen receptor (ER)+/HER2+ into a fast-growing ER-/HER2+ type that aggressively spreads or metastasizes to other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news

BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study finds mechanism leading to herceptin resistance and Rx approach to reverse it
(Louisiana State University Health Sciences Center) Research conducted by an international team of scientists discovered a mechanism that leads to Herceptin resistance, representing a significant clinical obstacle to successfully treating HER2-positive breast cancer. They also identified a new approach to potentially overcome it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news

Primary Breast Tumors Often Switch HER2 Status on Relapse Primary Breast Tumors Often Switch HER2 Status on Relapse
A substantial proportion of primary breast tumors switch from HER2-0 to HER2-low expression upon relapse, possibly widening the opportunity to treat patients with novel agents.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options
(European Society for Medical Oncology) The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2021 Category: Cancer & Oncology Source Type: news

FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Is HER2-Positive Good or Bad?
Title: Is HER2-Positive Good or Bad?Category: Diseases and ConditionsCreated: 5/5/2021 12:00:00 AMLast Editorial Review: 5/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 5, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news

Effect of COVID - 19 on Breast Cancer Treatment Examined
More patients with estrogen receptor - positive, HER2 - negative breast cancer treated with neoadjuvant endocrine therapy due to COVID - 19 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news

Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer
Did patients with locally advanced or metastatic breast cancer realize improvements in progression-free survival after treatment with this triple combination therapy?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

Is HER2 Cancer Aggressive?
Title: Is HER2 Cancer Aggressive?Category: Diseases and ConditionsCreated: 4/26/2021 12:00:00 AMLast Editorial Review: 4/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 26, 2021 Category: Cancer & Oncology Source Type: news

What Causes HER2 Positive Breast Cancer
What Causes HER2-Positive Breast Cancer? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 21, 2021 Category: General Medicine Source Type: news

Can HER2-Positive Breast Cancer Be Cured?
Title: Can HER2-Positive Breast Cancer Be Cured?Category: Diseases and ConditionsCreated: 4/9/2021 12:00:00 AMLast Editorial Review: 4/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 9, 2021 Category: Cancer & Oncology Source Type: news

'A life-changer': NHS England rolls out five-minute breast cancer treatment
New ‘quicker and kinder’ treatment combining drugs cuts length of time some patients have to spend in hospitalA new breast cancer treatment will cut the amount of time some patients have to spend in hospital from two and a half hours to five minutes.The treatment, called Phesgo, is being rolled out across England by the NHS and will be offered to breast cancer patients undergoing chemotherapy. It will be available to people with HER2-positive breast cancer, which accounts for 15% of all such cancers.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 5, 2021 Category: Science Authors: PA Media Tags: Breast cancer NHS Health Society Source Type: news

Is Chemo Necessary for HER2 Positive?
Title: Is Chemo Necessary for HER2 Positive?Category: Diseases and ConditionsCreated: 4/1/2021 12:00:00 AMLast Editorial Review: 4/1/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 1, 2021 Category: Cancer & Oncology Source Type: news

Prognostic value of molecular classification in metastatic breast cancer confirmed
(University of Barcelona) In a study published in the Journal of Clinical Oncology, researchers from the Hospital Cl í nic-IDIBAPS, University of Barcelona and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-like). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2021 Category: Cancer & Oncology Source Type: news

T cell circuits that sense antigen density with an ultrasensitive threshold
Overexpressed tumor-associated antigens [for example, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)] are attractive targets for therapeutic T cells, but toxic "off-tumor" cross-reaction with normal tissues that express low levels of target antigen can occur with chimeric antigen receptor (CAR)–T cells. Inspired by natural ultrasensitive response circuits, we engineered a two-step positive-feedback circuit that allows human cytotoxic T cells to discriminate targets on the basis of a sigmoidal antigen-density threshold. In this circuit, a low-affinity synthetic No...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Hernandez-Lopez, R. A., Yu, W., Cabral, K. A., Creasey, O. A., Lopez Pazmino, M. d. P., Tonai, Y., De Guzman, A., Mäkelä, A., Saksela, K., Gartner, Z. J., Lim, W. A. Tags: Molecular Biology reports Source Type: news

Weight Loss Tied to Worse Breast Cancer Outcomes
MONDAY, March 8, 2021 -- Weight loss during treatment and over two years of follow-up negatively impacts clinical outcomes among women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2
(Vall d'Hebron Institute of Oncology) VHIO investigators report how HER2 breast cancer cells adopt a strategy to resist clearance by redirected lymphocytes. Findings evidence that the disruption of interferon-gamma signaling confers resistance to these immunotherapies and promotes disease progression. Reported in Nature Communications, these results could help to potentiate future immune-based strategies and more precisely identify those patients who would be most likely to benefit from them. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news